IGC Pharma, Inc. (NASDAQ:IGC)

PRESS RELEASE

published on 11/14/2024 at 14:30, 1 year 9 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
IGC Pharma, Inc. announces Q2 FY2025 financial results and strategic advancements including breakthroughs in Alzheimer's treatment pipeline. Revenue grows 42% to $412k. R&D expenses decrease 28%

Financial Results R&D Expenses Q2 FY2025 IGC Pharma Alzheimer's Treatment
BRIEF

published on 11/06/2024 at 14:35, 1 year 9 months ago

IGC Pharma met en avant des avancées stratégiques dans les thérapies contre la maladie d'Alzheimer et la perte de poids

Intelligence Artificielle Perte De Poids Agonistes Du GLP-1 IGC Pharma Traitement De La Maladie D'Alzheimer
BRIEF

published on 11/06/2024 at 14:35, 1 year 9 months ago

IGC Pharma Highlights Strategic Advances in Alzheimer's and Weight Loss Therapies

Weight Loss Artificial Intelligence GLP-1 Agonists IGC Pharma Alzheimer's Treatment
PRESS RELEASE

published on 11/06/2024 at 14:30, 1 year 9 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
IGC Pharma, Inc. (NYSE American: IGC) announces a new interview with CEO Ram Mukunda discussing strategic expansion into metabolic and neurological markets, focusing on Alzheimer's and weight loss therapies, leveraging AI for diverse pipeline

Interview Neurodegenerative Disorders Metabolic Disorders IGC Pharma Ram Mukunda
BRIEF

published on 10/17/2024 at 14:35, 1 year 10 months ago

IGC Pharma étend son essai sur la maladie d'Alzheimer au Canada grâce à un partenariat avec Baycrest

IGC Pharma IGC-AD1 Essai Sur La Maladie D'Alzheimer Partenariat Baycrest Phase 2 Clinique
BRIEF

published on 10/17/2024 at 14:35, 1 year 10 months ago

IGC Pharma Expands Alzheimer's Trial to Canada with Baycrest Partnership

IGC Pharma Alzheimer's Trial IGC-AD1 Baycrest Partnership Phase 2 Clinical
PRESS RELEASE

published on 10/17/2024 at 14:30, 1 year 10 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
IGC Pharma expands Phase 2 trial to Canada at Baycrest Academy for Research and Education in Toronto, Ontario, to investigate IGC-AD1 for treating agitation in Alzheimer's dementia

Phase 2 Trial Alzheimer's IGC Pharma Agitation Treatment Baycrest Academy
BRIEF

published on 10/03/2024 at 15:05, 1 year 10 months ago

IGC Pharma Secures Two Awards in NIH's AI PREPARE Challenge

AI Technology Healthcare Innovation IGC Pharma Alzheimer's Prediction NIH Challenge
BRIEF

published on 10/03/2024 at 15:05, 1 year 10 months ago

IGC Pharma remporte deux prix lors du concours AI PREPARE Challenge du NIH

Technologie De L'IA Innovation Dans Le Domaine De La Santé IGC Pharma Prédiction De La Maladie D'Alzheimer Défi Du NIH
PRESS RELEASE

published on 10/03/2024 at 15:00, 1 year 10 months ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
IGC Pharma, Inc. wins 2 awards in the PREPARE Challenge for Alzheimer's research with its MHAS entry. Recognition highlights leadership in AI for disease prediction

Artificial Intelligence Healthcare Innovation Alzheimer's Research IGC Pharma PREPARE Challenge

Published on 08/24/2026 at 07:45, 3 hours 4 minutes ago

Sinopec Achieves Solid Operating Results in the First Half of 2026
Published on 08/22/2026 at 05:50, 2 days 4 hours ago

Battery X Metals Provides Board of Directors Update
Published on 08/22/2026 at 04:55, 2 days 5 hours ago

Vanta Announces Closing of First Tranche of Private Placement and Board of Directors Update
Published on 08/22/2026 at 00:30, 2 days 10 hours ago

BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
Published on 08/21/2026 at 23:00, 2 days 11 hours ago

Tintina Mines Announces Voting Results from its Annual General and Special Meeting of Shareholders

View all ACCESSWIRE

Published on 08/24/2026 at 10:35, 14 minutes ago

Camel Group's 12V Sodium-Ion Battery Selected for European OEM Pre-Development Project
Published on 08/24/2026 at 10:05, 44 minutes ago

Jungbunzlauer improves EcoVadis score and remains among the top 2% of companies worldwide
Published on 08/24/2026 at 09:35, 1 hour 14 minutes ago

2026 Taiwan Jewellery & Gem Fair to Take Place in November
Published on 08/24/2026 at 09:00, 1 hour 48 minutes ago

Original-Research: SYNBIOTIC SE (von NuWays AG): Under review
Published on 08/24/2026 at 09:00, 1 hour 49 minutes ago

Original-Research: Nabaltec AG (von NuWays AG): BUY

View all EQS

Published on 08/21/2026 at 18:33, 2 days 16 hours ago

260821 BENETEAU Transaction sur actions propres
Published on 08/21/2026 at 08:30, 3 days 2 hours ago

Thales issues a €1bn bond
Published on 08/21/2026 at 08:30, 3 days 2 hours ago

Thales émet un emprunt obligataire de 1 Md€
Published on 08/18/2026 at 18:00, 5 days 16 hours ago

KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 5 days 17 hours ago

Mise à disposition du rapport financier annuel 2025-26

View all LES ECHOS COMFI WIRE

News